Soleno Therapeutics (SLNO) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SLNO shares.
View SLNO analyst ratings or view top-rated stocks.

2 equities research analysts have issued 1-year price targets for Soleno Therapeutics' stock. Their SLNO share price forecasts range from $35.00 to $39.00. On average, they anticipate the company's stock price to reach $37.00 in the next year. This suggests a possible upside of 25.4% from the stock's current price.
View analysts price targets for SLNO or view top-rated stocks among Wall Street analysts.

Soleno Therapeutics' stock was trading at $1.98 at the beginning of 2023. Since then, SLNO stock has increased by 1,390.4% and is now trading at $29.51.
View the best growth stocks for 2023 here.

Soleno Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 200,500 shares, an increase of 151.9% from the August 31st total of 79,600 shares. Based on an average daily volume of 699,300 shares, the days-to-cover ratio is currently 0.3 days. Approximately 2.5% of the company's stock are sold short.
View Soleno Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our SLNO earnings forecast.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.11.

Shares of Soleno Therapeutics reverse split before market open on Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SLNO stock can currently be purchased for approximately $29.51.

Soleno Therapeutics (NASDAQ:SLNO) has a market capitalization of $294.80 million. The company earns $-24,070,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis.

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The official website for the company is www.soleno.life. The company can be reached via phone at (650) 213-8444, via email at ir@soleno.life, or via fax at 650-213-8383.